uniQure N.V. Ordinary Shares vs Rocket Companies Inc. Class A Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B), while Rocket Companies Inc. Class A Common Stock trades at $10.68 (market cap $29.82B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 20.6× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| QURE | RKT | |
|---|---|---|
Market Cap | $1.45B | $29.82B |
Volume | 3,323,243 | 46,995,062 |
Sector | Health | Financials |
52-Week High | $70.59 | $23.44 |
52-Week Low | $9.03 | $10.53 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $707.46M | $59.81B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →